A team of scientists led by SNBTS director Marc Turner, M.D., Ph.D. is heading the project, which reflects the combined efforts of the BloodPharma consortium, which has benefited from a Strategic Award, provided by the Wellcome Trust, in the amount of £5 million (approximately $8.4 million).It's a study to test transfusions using small amounts of blood (5mL), but nevertheless it will be real stem cell derived blood.
The research funded by the award involves multiplying and converting pluripotent stem cells into red blood cells for use in humans, with the aim of making the process scalable for manufacture on a commercial scale.
I called it back in 2010.
